XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
  Hypertension
  CAD
  Myocardial Infarction
  CHF
  Clinical Trials
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Aug 19th, 2006 - 22:18:38

A public health alert from the American College of Cardiology

Clinical Trials Channel
subscribe to Clinical Trials newsletter

Latest Research : Cardiology : Clinical Trials

   DISCUSS   |   EMAIL   |   PRINT
Patients should not discontinue clopidogrel without consultation
Mar 18, 2006, 02:40, Reviewed by: Dr. Rashmi Yadav

. Although the CHARISMA trial showed no benefit to combining Plavix® and aspirin and for certain patients, this study does not invalidate use of the drug for approved indications, such as stenting.

 
Recent media reports regarding the results of the CHARISMA Trial may be misinterpreted by patients with coronary stents and other conditions*, causing these patients to inappropriately stop taking the anti-clotting drug clopidogrel (Plavix®). Patients taking Plavix® for any reason should consult with their cardiologist or other health care provider before stopping this medication.

The CHARISMA Trial was presented at the Annual Scientific Sessions of the American College of Cardiology on Sunday, March 12 in Atlanta and simultaneously published in the New England Journal of Medicine. Although the CHARISMA trial showed no benefit to combining Plavix® and aspirin and for certain patients, this study does not invalidate use of the drug for approved indications, such as stenting. Certain other patients are given Plavix® after hospitalization for heart attack or stroke. Patients with these conditions must discuss the benefits and risks of anti-clotting medication with their health care provider and should not stop Plavix® on their own. Discontinuation of Plavix® in patients with recently-placed stents can cause clot formation within the stent, resulting in serious harm or death.

* According to the 2006 ACC/AHA/SCAI Guideline Update for Percutaneous Coronary Intervention (PCI), Class I recommendations indicate the use of aspirin and clopidigrel in patients undergoing angioplasty with stent implantation (contraindications include aspirin resistance, allergy or risk of bleeding).
 

-
 

http://www.acc.org/

 
Subscribe to Clinical Trials Newsletter
E-mail Address:

 

About the American College of Cardiology
The American College of Cardiology, a 33,000-member nonprofit professional medical society and teaching institution, is dedicated to fostering optimal cardiovascular care and disease prevention through professional education, promotion of research, leadership in the development of standards and guidelines, and the formulation of health care policy.


Related Clinical Trials News

Pre hypertension best managed by early pharmacological intervention
Patients should not discontinue clopidogrel without consultation
Clopidogrel and aspirin combination fails to show long term beneficial affects in stable vascular patients
Bluhm Cardiovascular Institute Surgeons Implant Heart Pump in Comparative Study of Two Devices
Ground-breaking heart stem cell trial (REGENERATE) now underway


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us